ArticleIndian journal of psychiatry2025
Outpatient-based buprenorphine-assisted opioid withdrawal management: A preliminary prospective observational study.
Article in Indian journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Indian guidelines mention the use of buprenorphine in opioid withdrawal in both outpatient and inpatient setting. Aim: This is the first study aiming at assessing the feasibility aspects of outpatient-based buprenorphine-assisted opioid withdrawal treatment for opioid dependence. Methods: In this prospective observational study, 30 men with opioid dependence, planned for outpatient-based withdrawal management, were recruited by purposive sampling and were assessed at baseline, 2, 4, and 12 weeks using validated tools. Abstinence was validated by a urine toxicology screen. Results: The median age of the sample was 24 (21.75-28.0) years. About 67% retained in treatment with a treatment perception score of 4.1 (4.0-4.4) and a significant reduction of craving and withdrawal scores. More than 80% were abstinent at 12 weeks. Conclusion: The study findings suggest that outpatient-based buprenorphine-assisted acute opioid withdrawal management is a feasible and acceptable treatment. Considering the relatively few inpatient addiction treatment settings, the findings are promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.